167: Effect of maternal SSRI antidepressants on p11 expression in the fetal brain

      The use of SSRIs for depression in pregnancy remains a therapeutic challenge. Fetal exposure to maternal SSRIs have been implicated in the disruption of cognitive and physiologic domains during fetal development. The protein p11 (s100a10) interacts with the 5-HT1B (htr1b) serotonin (5-HT) receptor, regulating its localization to the cell surface. 5-HT signaling through this receptor modulates fetal brain axonal circuit formation. SSRI therapy has been shown to indirectly regulate p11 levels in the adult brain. Our objectives were to determine 1) whether p11 is expressed in the fetal mouse brain, 2) whether maternal SSRI administration affects its expression and, 3) the consequences on 5-HT1B-mediated signaling.
      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic and Personal
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'


      Subscribe to American Journal of Obstetrics & Gynecology
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect